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        Caveolae are 50  –  100-nm-long invaginations of 
the plasma membrane (  1  ) that are important 
regulators of endocytosis (  2  ) and signal trans-
duction (  3  ). There are three caveolin family 
members, caveolin-1 (Cav-1), which is pre-
dominantly expressed in adipocytes, vascular 
smooth muscle, endothelial cells (ECs), and 
fi  bro  blasts; Cav-2, which is expressed in many 
cells that express Cav-1; and Cav-3, which is 
specifi  cally expres  sed in skeletal, cardiac, and, 
to a lesser extent, in vascular smooth muscle. 
Cav-1 and -3 are essential for caveolae forma-
tion (  4  –  6  ) in cells that express these isoforms, 
whereas Cav-2 is not absolutely required (  7  ). 
  Recent insights into the physiological roles of 
caveolae/caveolins have been dissected in these 
genetically modifi  ed mice. Although Cav-1 and 
-3 are essential for caveolae formation, they are 
dispensable during vascular and organ develop-
ment. The loss of Cav-1/caveolae, which is the 
primary isoform in the vascular system, results 
in dysregulation of nitric oxide (NO) synthesis, 
cell proliferation, enhanced vascular permeability, 
and pulmonary and cardiac functions, and it 
impairs liver regeneration (  4, 5, 8  –  13  ). These 
studies validate the in vivo importance of caveo-
lae and Cav-1 beyond cell-based studies that are 
largely hampered by operational defi  nitions of 
biochemical fractions containing caveolins and 
the lack of specifi  city inherent in reagents that 
extract cholesterol from cells (  14  ). 
  Vascular ECs constitute the surface mono-
layer of vasculature facing the blood and es-
sential roles in the regulation of blood fl  ow, 
blood pressure, and maintaining a selective 
permeability to macromolecules. EC barrier 
dysfunction results in various human diseases, 
including infl   ammation, tumor angiogenesis, 
and atherosclerosis. Indeed, the predominant 
phenotypes observed in Cav-1  –  defi  cient mice 
are vascular, cardiac, and pulmonary, and they 
may be caused by loss of caveolae in various cell 
types. Recent work from our group has shown 
that Cav-1 KO mice have impaired mechano-
transduction, fl  ow-dependent remodeling, and 
EC calcium infl  ux via transient receptor potential 
CORRESPONDENCE  
  William C. Sessa: 
 william.sessa@yale.edu
  Abbreviations used: Ach, acetyl-
choline; cGMP, cyclic guanos-
ine monophosphate; EC, 
endothelial cell; eNOS, en-
dothelial NOS; ERK, extracel-
lular signal-related kinase; JNK, 
Jun N-terminal kinase; LV, left 
ventricular; MAPK, mitogen-
activated protein kinase; NO, 
nitric oxide; NOS, NO syn-
thase; PE, phenylephrine; 
PECAM, platelet/EC adhesion 
molecule; RV, right ventricular; 
TG, transgenic. 
      The online version of this article contains supplemental material.   
  Reexpression of caveolin-1 in endothelium 
rescues the vascular, cardiac, and pulmonary 
defects in global caveolin-1 knockout mice 
  Takahisa Murata, Michelle I. Lin, Yan Huang, Jun Yu, Phillip Michael Bauer, 
Frank J. Giordano, and William C. Sessa 
  Department of Pharmacology and Program in Vascular Cell Signaling and Therapeutics, Boyer Center for Molecular Medicine, 
Yale University School of Medicine, New Haven, CT 06511   
  Caveolin-1 (Cav-1) is the principal structural component of caveolae organelles in 
smooth muscle cells, adipocytes, fi  broblasts, epithelial cells, and endothelial cells (ECs). 
Cav-1  –  defi  cient (Cav-1 knockout [KO]) mice are viable and show increases of nitric 
oxide (NO) production in vasculature, cardiomyopathy, and pulmonary dysfunction. In 
this study, we generated EC-specifi  c Cav-1  –  reconstituted (Cav-1 RC) mice and reexam-
ined vascular, cardiac, and pulmonary phenotypes. Cav-1 KO pulmonary arteries had 
decreased smooth muscle contractility and increased endothelial NO synthase activation 
and hypotension; the latter two effects were rescued completely in Cav-1 RC mice. 
Cav-1 KO mice exhibited myocardial hypertrophy, pulmonary hypertension, and alveolar 
cell hyperproliferation caused by constitutive activation of p42/44 mitogen-activated 
protein kinase and Akt. Interestingly, in Cav-1 RC mice, cardiac hypertrophy and pul-
monary hypertension were completely rescued, whereas alveolar hyperplasia was par-
tially recovered because of the lack of rescue of Cav-1 in bronchiolar epithelial cells. 
These results provide clear physiological evidence supporting the important role of cell 
type  –  specifi  c Cav-1 expression governing multiple phenotypes in the vasculature, heart, 
and lung. 2374 REGULATION OF PARENCHYMAL FUNCTIONS BY ENDOTHELIAL CAVEOLIN-1 | Murata et al.
WT arteries under resting and Ach-stimulated conditions (3      M 
for 3 min). Again, EC-specifi  c Cav-1 RC suppressed this 
increase in cGMP. In all of the strains, the sensitivity of the 
soluble guanylyl cyclase was normal because the increases in 
cGMP production in response to the NO donor sodium nitro-
prusside (1      M for 3 min) were similar. 
channels; these eff  ects are rescued by breeding global Cav-1 KO 
to EC-specifi  c Cav-1 transgenic (TG) mice (  15  ) to recon-
stitute Cav-1 (called Cav-1 RC) back into the endothelium 
(  11, 16  ). We show that EC-specifi  c Cav-1 reconstitution 
corrects the abnormal vasomotion in vessels and the cardiac 
and pulmonary abnormalities observed in Cav-1 KO mice, 
demonstrating that the diverse cardiovascular phenotypes in 
these mice are attributable to caveolae in the endothelium 
and not to other cell types that express Cav-1. 
    RESULTS   
  Generation of TG mice expressing EC Cav-1 on a Cav-1  –
  defi  cient background 
  To assess the eff  ects of Cav-1/caveolae on vascular, lung, 
and cardiac phenotypes, mice defi  cient in Cav-1 were bred 
to TG mice expressing Cav-1 in ECs alone, as previously 
reported (  11, 16  ).   Fig. 1 A   documents Cav-1 protein ex-
pression in intrapulmonary arteries isolated from these mice.   
WT mice demonstrate the presence of Cav-1 (  Fig. 1 A  , left 
column, green channel) predominantly in the endothelium 
and lower levels in smooth muscle (  n     5;   Fig. 1 A,   top, 
Cav-1 alone; middle, labeling of smooth muscle      -actin [red] 
and nuclei [DAPI, blue]; bottom, merged images), whereas 
Cav-1 KO mice (middle column) lack Cav-1 immuno-
staining in both layers (  n     5). Reconstitution of Cav-1 into 
the endothelium generated by crossing Cav-1 KO to EC-
specifi  c Cav-1 TG mice reintroduces Cav-1 into the endo-
thelium, but not into smooth muscle layers marked by 
     -smooth muscle actin staining (  n     5, right column). Insets 
show higher magnifi  cations of images to emphasize correct 
targeting of the transgene. 
  Effects of EC-specifi  c Cav-1 reconstitution on smooth 
muscle contractility and endothelium-dependent relaxation 
  Next, we examined how endothelium-specifi  c Cav-1 recon-
stitution infl  uences vasoreactivity, as there are biochemical 
and genetic data supporting a role of Cav-1 in regulating 
vascular function, including endothelial NO production and 
smooth muscle contraction. As shown in   Fig. 1 (B and C)  , 
0.01  –  10      M phenylephrine (PE) and 15  –  65 mM KCl in-
duced dose-dependent increases in isometric contractions in 
intrapulmonary arteries and responses to PE and KCl were 
reduced in vessels from Cav-1 KO mice. Interestingly, EC-
specifi  c Cav-1 RC was more responsive to PE than Cav-1 
KO, but this did not occur with KCl as the agonist. Next, 
we examined acetylcholine (Ach)-induced endothelium-
dependent relaxations in these vessels. As seen in   Fig. 1 D  , 
using PE as a contractile agonist, or in   Fig. 1 E  , using KCl as 
a contractile agonist, Ach-induced relaxations were aug-
mented in Cav-1 KO vessels, and eff  ects were normalized in 
Cav-1 RC mice. 
  Next, we measured cyclic guanosine monophosphate 
(cGMP) accumulation in intact vascular rings as a surrogate 
assay to quantify bioreactive NO production in intact pulmo-
nary arterial rings (  Fig. 1 F  ) and confi  rmed a signifi  cant in-
crease in bioactive NO in Cav-1 KO arteries compared with 
  Figure 1.     Characterization of pulmonary artery function in Cav-1 
KO and Cav-1 RC mice. (A) Cav-1 (green) and smooth muscle     -actin 
(red) localization in WT, Cav-1 KO, and Cav-1 RC pulmonary arteries in 
cross sections by immunostaining (B and C). Bar, 20      m. Insets show 
higher magnifi  cation images of section. Nuclei (blue) are detected via 
DAPI labeling. PE- (B) and high K       –  induced (C) contractions in WT, Cav-1 
KO, and Cav-1 RC pulmonary arteries. Ach-induced relaxations in WT, 
Cav-1 KO, and Cav-1 RC pulmonary arteries. The arteries were precon-
tracted with PE (D) or high K      (E), and Ach-induced relaxations were ex-
amined. (F) cGMP production in Cav WT, KO, and RC pulmonary arteries. 
*, P       0.05, compared with WT vessels;   †  , P       0.05, compared with Cav-1 
KO vessels. Data are expressed as the mean   the SEM.     JEM VOL. 204, October 1, 2007 
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and right columns). Cav-1 KO vessels exhibited no Cav-1 
immunoreactivity (  n     5). The pattern of eNOS labeling 
largely colocalized with GM 130 (  Fig. 2 B  , right) compared 
with WT and Cav-1 RC endothelium. 
  Next, we performed semiquantitative Western blotting 
for all caveolins in pulmonary arteries from WT, Cav-1 KO, 
and Cav-1 RC mice. As shown in   Fig. 2 C  , both Cav-1 and 
-2 levels were reduced in Cav-1 KO pulmonary arteries 
caused by the importance of Cav-1 in stabilizing Cav-2 levels 
(  19, 20  ); eff  ects were partially rescued in the Cav-1 RC ves-
sels. However, Cav-3 and      -actin (as loading controls) levels 
were not diff  erent in the three genotypes of mice, nor were 
the protein levels of eNOS, HSP90, and the protein kinase 
Akt. However, the phosphorylation levels of eNOS (on the 
Akt and AMPK phosphorylation site S1177) and Akt (on 
S473) were increased in vessels from Cav-1 KO mice, indi-
cating their activation (  Fig. 2, C and D  ); this is an eff  ect res-
cued in Cav-1 RC mice. 
  Body weight and cardiac and pulmonary abnormalities 
are markedly improved in Cav-1 RC mice 
  In addition to vascular abnormalities, Cav-1 KO mice have 
lower body weight (  8  ) and cardiac and pulmonary dysfunc-
tion. As shown in   Table I  , body weight was slightly lower in 
20-wk-old Cav-1 KO compared with age-matched WT mice, 
and Cav-1 RC mice recovered this weight loss (  n   = 7  –  9).   Cav-1 
KO mice exhibit left ventricular (LV) and right ventri  cular 
(RV) cardiac hypertrophy (  Fig. 3 A   and   Table I  ) using several 
measurements, including heart/body weight, RV/LV + septa, 
RV/body weight, and LV + septa/body weight, as previ-
ously reported (  21  ).   In addition, the diameter of the main 
coronary artery and coronary artery wall thicknesses was 
greater in Cav-1 KO mice, which is consistent with impaired 
remodeling of carotid arteries (  11  ). EC-specifi  c Cav-1 RC 
rescued these cardiac and vascular abnormalities to levels seen 
in age-matched WT mice. The lungs from Cav-1 KO mice 
were edematous with higher wet and dry weights and alveolar 
proliferation of the lower airways (  Table I  ). These results are 
consistent with increased lung edema and cellularity in Cav-1 
KO mice. Interestingly, EC-specifi  c Cav-1 RC partially res-
cued the pulmonary defects. 
  Gross morphological changes of the hearts and lungs 
of Cav-1 KO mice: partial rescue of the phenotypes 
in Cav-1 RC mice 
    Fig. 3   demonstrates heart and lung morphology in all of the 
strains examined. As mentioned in   Table I  , Cav-1 KO dis-
played hypertrophy of both the right and left ventricles (  Fig. 
3 A  ) and greater coronary wall thickness (typical images;   Fig. 
3 B  ;   Table I   for quantifi  cation of coronary wall thickness). 
EC-specifi  c Cav-1 RC improved these morphological end-
points. Similar to the heart, the lungs of Cav-1 KO mice exhibited 
cellular hyperproliferation in the alveolar area, bronchial epi-
thelial layer (  Fig. 3 B  ; indicated by B), and vascular layers 
(A indicates the artery, as seen in the typical images in   Fig. 
3 C   and the summary of alveolar area in   Table I  ). Interestingly, 
  eNOS protein localization in endothelium and signaling 
to eNOS in Cav-1 KO is rescued in Cav-1 RC mice 
  Next, we used whole-mount immunofl  uorescent staining to 
examine the infl  uence of Cav-1 KO and RC on endothelial 
NO synthase (eNOS) localization in intact endothelium lin-
ing intrapulmonary arteries. eNOS is typically colocalized on 
the Golgi complex and in Cav-1  –  positive plasmalemmal micro-
domains in vivo (  11, 17, 18  ).   Fig. 2 (A and B)   demonstrates 
eNOS/Cav-1 (  Fig. 2 A  ) and eNOS/GM130 (a peripheral 
membrane protein of Golgi complex) double-immunostain-
ing (  Fig. 2 B  ) in the endothelium of intact pulmonary arteries.   
WT and Cav-1 RC had similar levels of immunoreactive 
Cav-1 in ECs (  n     5 each;   Fig. 2 B  , middle row and left 
  Figure 2.     eNOS localization and activation in WT, Cav-1 KO, and 
Cav-1 RC pulmonary arteries. (A and B) eNOS (A and B, green), Cav-1 
(A, red), and GM130 (B, red) expression in WT, Cav-1 KO, and Cav-1 RC 
pulmonary arteries in situ by whole-mount immunostaining. Bar, 100 nm. 
Nuclei (blue) are detected via DAPI labeling (C) caveolins, eNOS, HSP90; 
Akt protein expression and eNOS (Ser  1179  ) and Akt (Ser  473 )  phosphorylation 
in WT, Cav-1 KO, and Cav-1 RC pulmonary arteries. These blots are repre-
sentative of four individual experiments. (D) Summary of eNOS and Akt 
phosphorylation-isolated vessels. Results are shown as phosphoprotein/
total protein for eNOS and Akt, respectively. *, P,       0.05, compared with 
WT vessels;   †  , P       0.05, compared with Cav-1 KO vessels. Data are ex-
pressed as the mean   the SEM.     2376 REGULATION OF PARENCHYMAL FUNCTIONS BY ENDOTHELIAL CAVEOLIN-1 | Murata et al.
pressure was higher in Cav-1 KO hearts compared with the 
other strains. In addition, RV end-diastolic pressures were 
elevated in Cav-1 KO, but heart rates and positive dp/dt 
were not diff   erent (Fig. S1, available at http://www.jem
.org/cgi/content/full/jem.20062340/DC1). In Cav-1 KO 
mice, systemic blood pressure was lower than WT and Cav-1 
RC mice (  Fig. 3 H  ). To assess whether this lower systemic 
arterial pressure was from enhanced eNOS activation in Cav-1 
KO or not, the eff  ect of the NOS inhibitor   N  -nitro-  l  -
arginine methyl ester on blood pressure as examined. Infusion 
of 10 mg/kg   N  -nitro-  l  -arginine methyl ester increased sys-
temic blood pressure to an equal extent in all strains and 
normalized the diff  erence in basal pressure seen in Cav-1 KO 
mice, suggesting that the lower systemic pressure is dependent 
on eNOS hyperactivation in Cav-1 KO. 
  Regulation of signaling in hearts and lungs from Cav-1 
KO and TG mice 
  Cav-1 and -2 are coexpressed in most types, including endo-
thelial and smooth muscle cells, whereas Cav-3 is enriched 
in muscle cells, especially in cardiac myocytes. Thus, the 
relative levels of caveolins in heart and lung homogenates 
(compared with three loading controls [     -actin, eNOS, and 
HSP90]) were assessed in all strains (  Fig. 4 A  , right, top three 
gels).   Cardiac and pulmonary tissue contained all three Cav 
isoforms, with more Cav-3 in the heart and more Cav-1 and 
-2 in the lung. The loss of Cav-1 reduced Cav-1 and -2 levels 
in both tissues. In both heart and lung, reconstitution of Cav-1 
to EC rescued Cav-1 and -2 protein expression, albeit to a 
lesser extent in heart, which is likely caused by the higher 
abundance of EC in lungs. The absence or presence of Cav-1 
expression did not aff  ect the levels of total eNOS, HSP90, 
Akt, p42/44 extracellular signal-related kinase (ERK), p38 
mitogen-activated protein kinase (MAPK), and Jun N-ter-
minal kinase (JNK) proteins (  Fig. 4 A  ), but did selectively 
EC-specifi  c Cav-1 RC partially rescued the bronchiole and 
alveolar hyperproliferation. Because the genetic rescue of 
these phenotypes was predicated on the proper targeting of 
the transgene to the endothelium in heart and lung, we ex-
amined immunoreactive Cav-1 in cardiac and pulmonary 
tissues from WT, Cav-1 KO, and Cav-1 RC mice. As seen 
in   Fig. 3 D   (heart) Cav-1 was expressed in cardiac vessels and 
capillaries (depicted in green channel, with      -smooth muscle 
actin in the red channel), was eliminated in Cav-1 KO, and 
was partially restored in Cav-1 RC hearts (arrowheads point 
out the presence of expressed transgene). In   Fig. 3 E  , Cav-1 
is expressed in the epithelial layers of bronchi (indicated by B) 
and in endothelial/smooth muscle layers (marked by cola-
beling with      -smooth muscle actin) of adjacent pulmonary 
arteries (indicated by A, left column), patterns that are absent 
in Cav-1 KO tissue (middle column). Reexpression of Cav-1 
in Cav-1 RC tissue was only detectable in the endothelial 
layer on arteries (indicated by A) and not in the bronchiole 
epithelium (  Fig. 3 E  , right column, arrowheads). 
  Correction of vascular leakage, pulmonary hypertension, 
and systemic blood pressure defects in Cav-1 RC mice 
  Because Cav-1 KO mice have enhanced basal vascular per-
meability, cardiac hypertrophy, and pulmonary hypertension, 
we quantifi  ed protein leakage, RV pressures, and systemic 
blood pressure in anesthetized WT, Cav-1 KO, and Cav-1 
RC mice. To assess vascular permeability, we used Evans 
blue extravasation into the interstitium of tissues. As seen in 
  Fig. 3 F  , Evans blue extravasation into the heart and lungs of 
Cav-1 KO mice were increased compared with WT mice, 
eff  ects rescued in Cav-1 RC mice. As shown in   Fig. 3 G  , 
baseline RV systolic pressure was elevated in Cav-1 KO, but 
reduced to WT levels in Cav-1 RC mice. Infusion of the 
positive inotrope dobutamine dose dependently increased 
RV systolic pressure in all strains, and the developed RV 
    Table I.        Cardiac and pulmonary parameters in WT, Cav-1 KO, and Cav-1 RC mice 
10 wk 20 wk
WT Cav-1 KO Cav-1 RC WT Cav-1 KO Cav-1 RC
Heart/body wt (mg/g) 4.60       0.11 5.07       0.06  b 4.66        0.07  a 3.97        0.09 5.07       0.08  b 3.98        0.03  a 
RV/LV + septa (mg/mg)  0.25       0.06 0.29       0.10  b 0.26        0.07  a 0.26        0.06 0.32       0.07  b 0.26        0.07  a 
RV/body wt (mg/g) 0.9           0.03 1.15       0.05  b 1.00        0.06  a 0.81        0.03 1.23       0.03  b 0.82        0.02  a 
LV + septa/body wt (mg/g) 3.69           0.09 3.92       0.06  b 3.72        0.07  a 3.16        0.07 3.85       0.12  b 3.16        0.08  a 
Coronary diameter (mm) 151.5           2.5 157.0           2.6 153.2           1.8 152.4           2.6 156.2           4.5 149.8           4.9
Coronary wall thickness (mm) 13.5           0.4 20.5           0.7  b 14.4            1.3  a 12.9        0.6 21.4       1.6  b 13.8        1.7  a 
Body wt (g) 24.9           0.4 24.9               0.1 24.8           0.3 34.1       0.7 30.2       1.4  b 35.1        0.9  a 
Lung wet wt (mg) 133.8           2.8 158.2               1.5  b 144.8            1.6  a 160.2            2.5 192.2           1.0  b 176.7                 2.4  a 
Lung dry wt (mg) 31.7           0.2 43.0           0.9  b 37.0        0.1  a 41.2        0.6 61.5       0.9  b 53.5        0.7  a 
Lung water content (mg) 102.1           2.4 115.2           1.5  b 107.8            1.4  a 119.0            2.2 131.7           1.1  b 121.2                1.9  a 
Alveolar area (%) 11.8           0.7 32.9           0.2  b 21.9        0.9  a 12.0        0.6 34.5       1.3  b 23.1        1.4  a 
The results of the experiments are expressed as the means       the SEM.   n     5  –  10 for all groups.
  a Signifi  cantly different from Cav-1 KO; P       0.05.
  b Signifi  cantly different from WT; P       0.05.JEM VOL. 204, October 1, 2007 
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of Cav-1 KO mice. In Cav-1 KO lungs, there was an in-
crease in immunoreactive pAkt (Ser  473  )- and p42/44 (Thr  202  /
Tyr  204  ) in pulmonary arteries (  Fig. 4, E and F  , top) and 
epithelium (middle and bottom). In lung extracts of Cav-1 
KO mice, there was elevated p38 MAPK (Thr  180  /Tyr  182  ) 
hyperphosphorylation, with no change in phospho-JNK 
levels. In contrast to the heart extracts, EC-specifi  c Cav-1 
RC mice only partially (phospho-Akt) or did not correct 
the elevated activation of p42/44 ERK or p38 MAPK in 
lung extracts. 
modulate the phosphorylation state of some of these pro-
teins. In Cav-1 KO hearts, Akt (Ser  473  ) phosphorylation and 
p42/44 (Thr  202  /Tyr  204  ) phosphorylation were elevated, but 
the phosphorylation states of p38 MAPK and JNK were not 
(  Fig. 4 B  ). Interestingly, in hearts from Cav-1 RC mice, acti-
vation of Akt and p42/44 ERK were restored to WT levels. 
The increased phospho-Akt and -ERK can also be detected 
in the main coronary arteries (  Fig. 4, C and D  ) and, to a 
much lesser extent, in cardiac fi  broblasts (Fig. S2, available at 
http://www.jem.org/cgi/content/full/jem.20062340/DC1) 
  Figure 3.     Heart and lung morphology and hemodynamics in WT, Cav-1 KO, and Cav-1 RC mice. (A  –  C) Hearts and lungs were stained with 
hematoxylin and eosin. (A) Low-magnifi  cation pictures of heart slices. (B) Cardiac muscle (top) and wall thickness of main coronary arteries (bottom). 
(C) Alveolar area (top) and large bronchioles (B, bottom) and arteries (A) in lung. (D and E). Cav-1 expression in WT, Cav-1 KO, and Cav-1 RC hearts (D) and 
lungs (E). Arrows delineate Cav-1 expression in Cav-1 RC mice. Nuclei (blue) are detected via DAPI labeling. These fi  gures are representative of 4  –  6 experi-
ments. Basal vascular permeability (F), right ventricle (RV) systolic pressure under nonstimulated and dobutamine-stimulated conditions (G), and mean 
systemic blood pressure (G) in Cav-1 WT, KO, and RC pulmonary arteries. Data are the means   the SEM.   n     4  –  6 mice per group. *, P       0.05,  compared 
with WT vessels;   †  , P       0.05, compared with Cav-1 KO vessels. Bars: (A) 1 mm; (B  –  E) 200     m.   2378 REGULATION OF PARENCHYMAL FUNCTIONS BY ENDOTHELIAL CAVEOLIN-1 | Murata et al.
  Figure 4.     Enhanced Akt and p42/44 ERK phosphorylation and fi  brogenic gene expression in hearts and lungs of WT, Cav-1 KO, and Cav-1 
RC mice. (A and B) Total caveolins, eNOS, HSP90, Akt, p42/44, p38, and JNK protein expression and phosphor-Akt (Ser  473  ), p42/44 (Thr  202 /Tyr 204 ),  p38 
(Thr  180 /Tyr 182  ) in tissue extracts. (A) Typical Western blots from six individual experiments; (B) the summary of these experiments by quantitative imaging. 
Akt (Ser  473  ) phosphorylation (C) and p42/44 (Thr  202 /Tyr 204  ) phosphorylation (D) in main coronary arteries of the three strains of mice, respectively. Akt (Ser  473 ) JEM VOL. 204, October 1, 2007 
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  There are biochemical and genetic data supporting a role 
for Cav-1 as a negative regulator of agonist-mediated eNOS 
activation (  4, 5, 10, 12, 23  –  25  ). Consistent with these re-
ports, eNOS hyperactivation was observed in Cav-1 KO 
pulmonary arteries as assessed by vascular relaxation experi-
ments, cGMP measurements, Western blotting for activated 
Akt (S473 phosphorylation) and eNOS (S1177 phosphoryl-
ation), and in vivo hemodynamic studies, phenotypes were 
completely rescued in Cav-1 RC mice. In addition, we show 
that Cav-1 defi  ciency impaired PE- and high K       –  induced 
vascular smooth muscle isometric tension generation in iso-
lated intrapulmonary arteries. Although contractile responses 
to PE, but not KCl, were improved in vessels from EC-spe-
cifi  c Cav-1 RC mice, the overall defect in vascular smooth 
muscle function was not restored, suggesting that this pheno-
type is EC independent and dependent on Cav-1 in vascular 
smooth muscle. This is consistent with reports in Cav-1 KO 
mice, showing impairment in calcium signaling (spontaneous 
transient oscillatory currents and capacitive calcium entry; 
reference [  16  ]) and contractility in vascular smooth muscle 
from isolated microvessels (  5  ). In Cav-1 KO vessels, the lev-
els of Cav-3 did not change, suggesting that Cav-3 was not 
responsible for this contractile defect in smooth muscle. 
  In the heart, Cav-1 is expressed in cardiac endothelium 
and fi  broblasts, but not in cardiomyocytes, where Cav-3 is the 
major isoform. In the lung, Cav-1 and -2 are expressed in the 
endothelium, most epithelial cells, and fi  broblasts, and Cav-3 
is present in airway and vascular smooth muscle. However, 
despite the paucity of Cav-1 in cardiomyocytes, Cav-1 KO 
mice display cardiac hypertrophy, pulmonary hypertension, 
and pulmonary hyperplasia associated with hyperactivation 
of the p42/p44 ERK  –  MAPK and Akt pathways, as well as 
cellular hyperproliferation and increased collagen gene ex-
pression in the lung. In respect to the cardiac phenotypes, 
using echocardiography and gated MRI, hearts from Cav-1 
KO mice exhibited concentric LV hypertrophy and dilated 
RV hypertrophy secondary to pulmonary hypertension (  21  ). 
Another independent study using echocardiography alone 
showed both dilated LV and RV dimensions in hearts of 
Cav-1 KO mice; the dilation was caused by pulmonary hyper-
tension (  10  ). Our data supports the role of the endothelium in 
these phenotypes because EC-specifi  c reconstitution of Cav-1 
lowered pulmonary pressure and normalized RV dilation 
and LV hypertrophy. However, the most direct evidence for 
the independent role of Cav-1 on cardiopulmonary func-
tion versus pulmonary hyperplasia and alveolar thickening is 
supported by data documenting that Cav-2 KO mice (which 
retain Cav-1 expression) do not have cardiac hypertrophy 
or pulmonary hypertension, but do exhibit pulmonary hy-
perplasia (  7  ). More importantly, we show that both cardiac 
  Increased signaling in Cav-1 KO mice is linked 
to hyperproliferation and collagen synthesis 
  To examine the link between the loss of Cav-1, activation 
of signaling pathways, and cell proliferation, sections from 
hearts and lungs were immunolabeled and quantifi  ed for the 
expression of the EC marker platelet/EC adhesion molecule-1 
(PECAM-1) and the epithelial cell marker E-cadherin (E-
cad;   Fig. 4 G   and Fig. S3, available at http://www.jem
.org/cgi/content/full/jem.20062340/DC1). In the heart, the 
number of PECAM-1  –  positive cells did not change in the 
three strains, but in the lung, Cav-1 KO lungs had increased 
numbers of ECs and epithelial cells per area of section ana-
lyzed. The increase in PECAM-1  –  positive, but not E-cad  –
  positive, cells in the lung was reduced in Cav-1 RC mice. 
Similar results were obtained using Western blotting for the 
EC marker VE cadherin and for E-cad (unpublished data). 
The data quantifying ECs and epithelial cells were recapitu-
lated by counting the total number of DAPI-stained nuclei 
per area in heart and lung sections (  Fig. 4 H  ). 
  Finally, because of the alveolar and septal changes observed 
in the lungs of Cav-1 KO mice and the recent study show-
ing that patients with idiopathic pulmonary fi  brosis exhibit 
a marked decrease in Cav-1 expression linked to up-reg-
ulation of TGF-      signaling (  22  ), we examined the ex-
pression of TGF-     1 and the interstitial collagens (I and III) 
via RT-PCR. As seen in   Fig. 4 I  , the expression of TGF-     1, 
type I collagen       1 chain (Col1A1),       3 chain (Col1A3), 
and type III collagen       1 chain (Col3A1) were increased in 
Cav-1 KO hearts and lungs. The increase in TGF-     1 and 
Col1A3 expression were rescued in the hearts by the trans-
gene, whereas Col1A1 and Col3A1 were partially rescued 
in the lung. 
    DISCUSSION   
  The lack of embryonic lethality in Cav-1 KO mice has al-
lowed investigators to test the importance of this protein 
and its corresponding organelle in several postnatal func-
tions. Several groups have independently generated Cav-1 
KO mice, and they have reported that Cav-1/caveolae KO 
mice possess clear and reproducible vascular, cardiac, and 
pulmonary phenotypes (  4, 5, 10  ). These phenotypes, driven 
by the global loss of Cav-1, may be caused by the loss of the 
gene from many cells that express it, including ECs, smooth 
muscle cells, adipocytes, fi  broblasts, and epithelial cells. Our 
fi  ndings argue that the major vascular, cardiac, and pulmo-
nary phenotypes in Cav-1 KO are largely caused by the loss 
of caveolae in the endothelium lining the vasculature of these 
organs, supporting the concept that endothelial Cav-1 can 
regulate paracrine functions governing remodeling of cardiac 
and pulmonary tissue. 
phosphorylation (E) and p42/44 (Thr  202 /Tyr 204  ) phosphorylation (F) in pulmonary arteries (top) and lung parenchyma (middle showing large airway and 
bottom showing alveoli). Photos are representative from four separate experiments. Quantitative analysis of PECAM-1 and E-cad (G) and total nuclei (H) 
in hearts and lungs of WT, Cav-1 KO, and Cav-1 RC mice. Expression of TGF-     1, and interstitial collagen genes (I) by RT-PCR (compared with GAPDH) in 
total RNA isolated from hearts and lungs of WT, Cav-1 KO, and Cav-1 RC mice. Data are the means   the SEM.   n     4 mice per group.     
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cell-specifi  c manner and strongly impacts cardiac size and 
pulmonary functions. These data support the idea that caveo-
lae are vital membrane microdomains that cluster or integrate 
signaling in vivo, as well as in vitro. 
  In conclusion, the generation of EC-specifi  c Cav-1 RC 
mice and correction of several phenotypes supports the idea 
that endothelial Cav-1 plays a central role in blood vessel, 
pulmonary, and cardiac functions. Whether the loss of Cav-1 
in endothelium leads to constitutive activation of all signaling 
in ECs (eNOS, ERK, Akt, and p38 MAPK) or if the loss 
of Cav-1 in endothelium exerts paracrine eff  ects on adjacent 
cardiac and pulmonary parenchyma, leading to the observed 
cardiac and pulmonary phenotypes, is not known and will be 
the focus of future studies. Additional studies generating cell-
specifi  c knockouts of Cav-1 and -2 or TG reexpression of these 
isoforms in non-ECs in the global knockout background will 
strengthen the idea that caveolins exert cell-specifi  c roles in 
signaling and function. 
    MATERIALS AND METHODS   
  Generation of Cav-1  –  defi  cient and EC-specifi  c Cav-1 RC animals.   
  Endothelial-specifi  c Cav-1 TG mice carrying canine Cav-1 transgene under 
the preproendothelin-1 promoter (  15  ) were crossed with F5 generation 
Cav-1  –  defi  cient mice (  5  ), as previously described (  11  ). All mice were geno-
typed for the presence of endogenous murine Cav-1, the presence of neo-
mycin cassette, and the presence of canine Cav-1 transgene using specifi  c 
PCR primers. Male mice (10 and 20 wk old) were used for the experiments. 
After anesthesia with 100 mg/kg ketamine/xylazine i.m. and PBS perfusion 
from RV under physiological pressure (    20 mmHg), all tissues (pulmonary 
artery, lung, and heart) were dissected and used for each experiments. All 
animal procedures were approved by the Yale Institutional Animal Care and 
Use Committee. 
  Tissue processing.     Hearts and lungs were removed en bloc. In some ex-
periments, lungs were blotted dry, weighed, and put on aluminum foil to dry 
overnight in the oven; dry weight of tissue is recorded the next day. The 
heart RV and LV plus septum (LV + septa) were separated and weighed. 
  Immunofl   uorescence and immunohistochemistry.     After dissection, 
intrapulmonary arteries, hearts, and lungs (from 10-wk-old mice) were fi  xed 
with 4% paraformaldehyde for 10 min at 4  °  C, and then dehydrated in 15% 
sucrose overnight at 4  °  C. The vessels were then embedded in OCT (Sakura) 
and fl  ash-frozen in a liquid nitrogen  –  cooled isopentane bath. 5-  μ  m sections 
were blocked with 3% normal goat serum. For immunofl  uorescence studies, 
the slides were incubated with rabbit anti-Cav-1 antibody (BD Transduction 
Laboratories), mouse anti  –       -smooth muscle actin antibody Cy3 conjugate 
(Sigma-Aldrich), rat anti  –  VE-cadherin antibody (BD PharMingen), and rat 
anti  –  E-cad antibody (1:200 dilution; 4  °  C for 12 h; Zymed Laboratories). 
Alexa Fluor 488 anti  –  rat/  –  rabbit IgG (Invitrogen) was used as secondary 
antibody (1:500 dilution; at room temperature for 1 h). For immunohis-
tochemistry, slides were probed with rabbit anti  –  phospho-Akt (Ser  473  ) 
antibody (Cell Signaling Technology) and anti  –  phospho-p42/44 (Thr  202  /
Tyr  204  ) antibody (1:200 dilution; 4  °  C for 12 h; Cell Signaling Technology). 
After the incubation with biotinylated anti  –  rabbit IgG (Jackson Immuno-
Research Laboratories), we probed the samples using the Nova Red staining 
kit (Vector Laboratories). 
  Whole-mount staining.     The intrapulmonary arteries (from 10-wk-old 
mice) were fi  xed with 4% paraformaldehyde (4  °  C for 10 min), permeabi-
lized with 0.3% Triton X-100 PBS (at room temperature for 30 min), and 
blocked by 3% normal goat serum containing PBS (at room temperature for 
morphometry and pulmonary hypertension are rescued in 
Cav-1 RC mice, strongly supporting a role for endothelial 
Cav-1 as the major cell type contribution to LV hyper  trophy 
and RV remodeling, secondary to pulmonary hypertension. 
In the context of pulmonary hyperplasia and lung remodeling, 
the benefi  cial eff  ect of the Cav-1 transgene may be caused by 
stabilizing Cav-2 in the endothelium, which then leads to a 
partial genetic rescue of the phenotype, which is consistent 
with a role of Cav-2 regulating alveolar hyperplasia. This 
could be directly tested by EC-specifi  c reexpression of Cav-2. 
Interestingly in the hearts and lungs of Cav-1 KO mice, gene 
expression of TGF-     1 and interstitial collagens I and III were 
elevated, eff  ects rescued in the hearts, but not lungs, which is 
consistent with the idea that abnormal TGF-      signaling may 
contribute to these phenotypes. 
  Another interesting fi  nding in our study was that vascular 
and cardiac abnormalities in Cav-1 KO mice were largely 
rescued in Cav-1 RC mice, but the lung abnormalities were 
only partially rescued. In the lung, the reintroduction of EC-
specifi  c Cav-1 stabilized Cav-2 levels and rescued pulmonary 
hypertension, and the enhanced lung permeability and edema, 
but only partially rescued the increased alveolar area, endo-
thelial (PECAM-1 staining), and alveolar (E-cad staining) 
hyper  plasia in Cav-1 KO mice. In lung extracts from Cav-1 
KO mice, the basal levels of pAkt, p42/p44 ERK, and p38 
MAPK activation were elevated compared with lungs from 
WT mice, and in Cav-1 RC mice, only lung pAkt activation 
was rescued. This suggests that a majority of the cells that 
contribute to increased Akt activity in Cav-1 KO are of vas-
cular origin, whereas activation of ERK and p38 MAPK oc-
curred primarily in epithelia or fi  broblasts. In lung tissue, EC 
and epithelial cells are the major cells expressing Cav-1 pro-
tein and epithelial Akt and p42/44 ERK were highly phos-
phorylated in Cav-1 KO lungs. EC-specifi  c Cav-1 RC did 
not aff  ect epithelial Cav-1 defi  ciency, and its proliferation as-
sociated with activation of Akt- and p42/44 ERK. Given 
recent evidence that a decrease in Cav-1 is associated with 
increased fi  brosis (  22, 26  ), we examined genes linked to fi  -
brosis in the three strains. Interestingly, in the hearts and 
lungs of Cav-1 KO mice, gene expression of TGF-     1 and 
interstitial collagens I and III were elevated; these eff  ects were 
rescued in the hearts, but not the lungs, which is consistent 
with the idea that abnormal TGF-      signaling may contribute 
to these phenotypes. 
  The idea that Cav-1/caveolae microdomains are impor-
tant for signal transmission from the cell surface originated 
from work in the Ras-ERK, G-protein, and eNOS path-
ways, but has extended to many other signaling pathways (  3  ). 
Because this work was, for the most part, performed in vitro 
with purifi  ed proteins and relied on fractionation procedures 
and the enrichment of Cav-1 and caveolae and the sensitivity 
of signaling pathways to agents that disrupt cholesterol syn-
thesis, it was met with much skepticism. Work in Cav-1 KO 
mice has convincingly shown that Cav-1 can negatively reg-
ulate ERK and eNOS activity; however, based on this study, 
Cav-1 also regulates Akt and p38 MAPK activation in a JEM VOL. 204, October 1, 2007 
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  Statistical analysis.     The results of the experiments are expressed as the 
means   ±   the SEM. Statistical evaluation of the data was performed by analysis 
of variance, followed by the Tukey posttest for comparison between groups 
using Prism 3.0. A value of P       0.05 was regarded as statistically signifi  cant. 
  Online supplemental material.     Fig. S1 shows cardiac function in Cav-1 
WT, KO, and RC mice. Fig. S2 shows phospho-42/44 phosphorylation 
in Cav-1 WT, KO, and RC heart interstitial fi  broblasts. Fig. S3 shows EC 
and epithelial cell proliferation in Cav-1 WT, KO, and RC heart and lung. 
The online version of this article is available at http://www.jem.org/cgi/
content/full/jem.20062340/DC1. 
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